Xenon Pharmaceuticals logo

Xenon Pharmaceuticals

XENE | NASDAQ
Chart Builder DCF Calculator
$39.26
-$1.22 (-3.01%)
At close: Nov 16, 2026, 4:00 PM ET
$39.05
-$0.21 (-0.53%)
After-hours: Nov 16, 2026, 7:30 PM ET
-3.01%

Rating

Updated: Nov 16, 2026
28.1
Fundamentals Weak
Market Sentiment Bullish
Moat None
Sector Rank #854/1021 (Top 84%)

Key Statistics

Market Data

Market Cap $3.86B
1D Range
39.12 40.61
52W Range
33.49 70.96

Valuation (TTM)

PE -8.35
PB 3.37
EV/EBITDA -6.70

Valuation (NTM)

Forward PE N/A
Forward PEG -1.15
Price Target $67.00
Loading financial charts...

Profile

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company op...

Sector Healthcare
Industry Biotechnology
Employees 364
IPO Date Nov 5, 2014
Fiscal Year January - December

Latest News

Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript

7 days ago · seekingalpha.com

Xenon Pharmaceuticals Inc. (XENE) Q3 2026 Earnings Call Transcript
Xenon Pharmaceuticals Q3 Earnings Call Highlights

7 days ago · marketbeat.com

Xenon Pharmaceuticals Q3 Earnings Call Highlights
Xenon to Present at Upcoming Investor Conferences

13 days ago · globenewswire.com

Xenon to Present at Upcoming Investor Conferences
Xenon to Report Q3 2026 Financial Results on November 9, 2026

14 days ago · globenewswire.com

Xenon to Report Q3 2026 Financial Results on November 9, 2026
Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

19 days ago · globenewswire.com

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain
Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

27 days ago · globenewswire.com

Wolf Popper LLP Continues Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

1 month ago · zacks.com

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors

2 months ago · newsfilecorp.com

Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

2 months ago · marketbeat.com

Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review

2 months ago · prnewswire.com

Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)

Earnings

Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
8
Consensus
Buy
Price Target
$67.00
Upside
+70.66%
Buy (7)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.